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Introduction:
Breast carcinoma continues to be the most frequently occurring carcinoma in women. Presently, approximately one in every eight women will develop the disease. 1 Great strides have been made in the treatment of breast carcinoma that have reduced the risk of recurrence and improved survival rates. The removal of axillary lymph nodes has been an integral part of breast carcinoma treatment since the end of the last century.
2 Axillary lymph nodes are removed to provide accurate information for staging, to accomplish local control, and for prognosis in order to plan adjunctive, systemic therapy. The status of the axillary lymph nodes remains the single most important predictor of survival.
3 Therefore, axillary treatment surgically and/or with radiotherapy is still an essential component in the management of most patients with invasive breast carcinoma. [4] [5] [6] Chronic edema of the arm, commonly called Lymphedema or post-mastectomy edema (PME), was described first as a side effect of mastectomy operations by Halsted in 1921. 7 Although there has been a trend toward more conservative surgery and greater use of radiotherapy, PME remains a common iatrogenic problem (Figure1).
Edema represents an increase in interstitial fluid volume sufficient to manifest with swelling. Any edema, whatever the underlying cause, is due to an imbalance between capillary filtration and lymph drainage. 8 Most examples of limb edema are caused by an increase in capillary filtration, overwhelming lymph drainage capacity. Lymphedema, however, strictly occurs when swelling is due to a failure of lymph drainage in circumstances in which capillary filtration is not increased.
The lymphatic system is a one-way drainage route designed to rid the "tissues" of unwanted material and excess fluid. It therefore represents a waste route and overflow pipe, with its essential function being to return to the blood vascular compartment protein, colloids, and particulate matter too large to reenter the blood compartment directly 9 ( Figure 2 ). Two types of lymphatic vessels exist: First, the smaller initial lymphatic, which includes the smallest lymphatic capillary and the larger pre-collector vessel, and second, the collecting lymphatic vessel into which the pre-collectors drain. 10 The collecting lymphatics are the main limb lymphatic vessels that provide the afferent flow to the lymph nodes. They behave like a series of smooth muscle hearts that are responsible for the propulsion of lymph centripetally. 11 Intrinsic pumping of collecting vessels is essential motor for lymph propulsion. For initial lymphatics, however, flow of interstitial fluid and macromolecules is caused by intermittent changes in hydrostatic and oncotic pressures locally. 12 Deformation or movement of the tissues by surface pressure or underlying muscle contractions and by other Figure 2 contractile structures, such as arterioles, causes expansion or compression of the initial lymphatics. The compression forces lymph along initial lymphatics. Valves in both, initial and collecting lymphatics ensure that flow is unidirectional. Lymphedema arises when an intrinsic fault develops within the lymph-conducting pathways (primary lymphedema) or when damage occurs from one or more factors originating outside the lymphatic system, such as surgical removal of lymph nodes (secondary lymphedema).
Lymphedema therefore, is a disease characterized by abnormal collections of fluid and proteins within the interstitial space. Treatment options for this debilitating condition have included drug therapy, physical therapy, and surgical approaches that have yielded limited success. Unfortunately, for lymphedema today, treatment options are all palliative, for there is no effective treatment that could offer a permanent cure to this disease.
Secondary Lymphedema resulting after iatrogenic, surgical disruption of the lymphatic vessels in breast cancer surgery, has continued to be neglected in the U.S. in spite of the fact that it has now become an acceptable diagnosis (ICD9-457.0). 13 Swelling of the upper limb, constitutes the most invalidating complication of breast carcinoma treatment. Untreated, upper extremity lymphedema predisposes women to the development of severe acute or chronic infections with limitations on functioning and serious disturbances in a patient's quality of life. Psychological distress (disfigurement), depression and social inhibition. [14] [15] It is estimated that 15-20% of the 2 million breast cancer survivors, are living currently with post-treatment lymphedema. [16] [17] The swollen arm, which can be as much as twice the normal size, is disfiguring and commonly causes functional impairment, psychosocial maladjustment and psychological morbidity. 18 Added to the physical symptoms that patients must cope with, is the pain caused unintentionally by clinicians that, interested in carcinoma recurrence, trivialize the non-lethal nature of lymphedema. 
Body:
Vascular Endothelium Growth Factor (VEGF) is produced by many different cell types both in tissue culture and in vivo. It binds to plasma membrane receptors on endothelial cells (EC) only with an extra cellular transmembrane glycoprotein linked to an intracellular tyrosine kinase domain, thus VEGF is an EC specific mitogen.
VEGF-C is a 38 kD homodimeric glycoprotein that is commercially available. This recombinant human VEGF-C is from a DNA sequence encoding the 165 amino acid residue variant of human VEGF expressed in Sf 21 insect cells using a baculovirus expression system. The product is lipolized from a sterile-filtered solution in 30% acotonitrile plus 0.1% TFA containing 50μg of cytokine. VEGF-C is of particular interest because it is a specific mitogen for lymphatic endothelium in adult tissues.
Angiopoietin-2 is a ligand for the endothelial Tie-2 receptor tyrosine kinase, it has a dual function in the processes of postnatal angiogenesis and vascular remodeling. Also Ang-2 signals are required for the proper development and function of lymphatic vessels. Recent data also suggest that the roles of Ang-2 and VGEF-C in the lymphatic vessel development are analogous too the roles of Ang-1 and VEGF in blood vessel development. Thus, Ang-2 is the first endothelial cell-specific growth factor demonstrated to function in vessel formation or regression depending on the tissue context. 19 In combination with VEGF-C, Ang-2 potentiates its effect.
Tissue engineering is an interdisciplinary field that incorporates principles of engineering and polymer chemistry into the biological sciences, in efforts to develop biological substitutes for failed tissues and organs. It is a new and rapidly expanding field, in which the techniques are being developed for culturing or promoting regeneration of a variety of tissues, both in vitro and in vivo using polymer "scaffolds" to support tissue growth. 20 Unlike the solid polymer systems currently used to create a cell-polymer construct, a liquid support matrix that polymerizes to a gel would have the potential for injectable delivery, which would be much less invasive than open implantation. Alginate hydrogels have been increasingly important in biotechnology applications, such as tissue engineering, artificial organs and as drug carriers. 21 Delivery rate can be predetermined and its local, rather than systemic administration be of great advantage (Alginates are approved by Food and Drug Administration for human use).
Alginate refers to a family of polyanionic copolymers derived from brown sea algae and comprising 1,4-linked β-D-manuronic (M) and α-L-glucoronic (G) acid residues in varying proportions. The fact that G and M are C5 epimers results in a switch-over of the monomer chair conformation, giving rise to all four possible glycosidic linkages and at the molecular level, large effects like cavity formations between G residues are observed. It has been shown that the occurrence of G and M within the alginate molecule is block-wise and not random. 22, 23 There is a direct dependence between the mechanical strength of an alginate gel and the porosity of the gel network. When gels are made from alginate rich in glucoronic (G) acid residues, higher moduli are obtained compared to gels made from alginates less enriched in G residues, and also higher diffusion rates. (Figure 3 ). Gelling properties of alginate are a function of the M/G composition and the sequential structure of M and G along the alginate chain (Figure 3) .
Figure 3
Alginate gel incorporation: Essentially there are two main methods for the preparation of alginate gels: The dialysis/diffusion method and internal geleation method. In the dialysis/diffusion method (diffusion setting) gelling ions are allowed to diffuse into the alginate solution. In our study we will incorporated sterile G (50%) and M (50%) copolymers of alginate to a solution with Potassium Phosphate and Sodium Chloride (0.1 M K 2 HPO 4 and 0.135 M NaCl, pH of 7.4), which was previously sterilized by autoclave. A 1.0% Sodium Alginate solution will then be mixed with 0.2 gm of CaSO 4 per milliliter, this solution will be placed in ice prior to extrusion. Because of all the different characteristics previously mentioned we decided to produce an alginate gel that would have the best properties of both, the G and M copolymers. Thus providing a gel that would be highly porous and relatively strong. Previously expanded EPC's which have been induce to differentiate into LEC by the growth factors, VEGF-C and Ang-2, will be incorporated into this gel for injection.
Animal Model for LEC harvest:
We continue to use the same animal model described last year to harvest the LEC to grow in culture to use in our in vitro studies.
Preliminary in vitro studies were carried out to determine the ideal Ang-2 concentration to be incorporated into the alginate gels. In vitro culture with LEC and three different concentrations (as recommended by Regeneron): 0.22 μg/ml, 0.67 μg/ml and 2 μg/ml of Ang-2 reveled that the proliferative and migratory response of the LEC was greater at 2 μg/ml when compared to the other two concentrations.
In general terms, an increase in G content (measured as G n>1 ) as well as in molecular weight will give a stronger gel. In contrast to most gelling polysaccharides, alginate gels have the particular feature of being "cold setting"'. This implies that the setting of alginate gel is more-or-less independent of temperature. With these initial results we determined that the concentrations of Ang-2 that should be incorporated into alginate gels should be the same as the ones above, and determine if the release of the growth factor from the alginate gel would result in the same or comparable proliferation and migration of LEC.
LEC's were cultivated with Ham's modified F12K medium for EC with ECGS. Cells were serum starved (from 10% to 1%FBS) prior to plating on the petri-dish with the alginate gels. Once again the ideal concentration for Ang-2 was that of 2 μg/ml, where the proliferation and migration of LEC was more profound.
Alginate gels were then prepared to incorporate VEGF-C at a concentration of 200 ng/ml and Ang-2 at a concentration of 2 μg/ml. These gels will now be used in vivo, in the mouse tail animal model we have worked on. Lymphedema animal model: A lymphedema mouse model was recently described in the literature. 24 This model provides a useful in vivo system, in which experimental treatments for lymphedema can be evaluated. We operated the tail of mice to cauterize the lymphatics and induce lymphedema ( Figure 5 ).
In this model, hairless mice (SKH1/Charles River Laboratories, Pittsfield, NH) weighing between 20 are 30g were used. The hairless mice offer the advantage that lymphedema development and subsequent tail diameter measurements are easier to follow. Anesthesia and Analgesia: The animals were anesthetized by placing them inside an induction chamber with 1.5% isoflurane and 100% Oxigen (JA Webster Inc., Sterling, MA). Once the animals were anesthetized they were placed in a prone position and the head placed inside a conical mask to maintain anesthesia (0.8% Isoflurane and 100% Oxigen). Analgesia was maintained post-op and for the next 7 consecutive days by daily subcutaneous (SC) injections of 3.3 mg/Kg butorphanol.
Prior to start the surgical procedure, 0.10 ml of 5% blue dextran 2M (Sigma, St. Louis, MO) in saline is injected SC into the tip of the tail in order to identify the lymphatic vessels. Then, the operative site at the base of the tail is cleansed with 70% ethanol and povidine/iodine, and a circumferential incision is made through the dermis to sever the superficial lymphatic network. The three deep lymphatic vessels located in the lateral and ventral aspects of the tail are isolated and destroyed by electrical cauterization. Finally, low cauterization is applied too the edges of the circumferential wound, which results in a 2-4 mm gap between the skin edges followed by secondary healing at the site (Figure 5,6 ). Figure 5 Once the lymphedema of the tail has been developed, the transplantation (SC injection) of the alginate gel containing the growth factors, VEGF-C and Ang-2 was performed in an attempt to induce lymphatic vessel proliferation and regeneration of the lymphatic network previously destroyed. Subsequent Lymphocintography studies would confirm if lymphatic flow had been restored. Acute Lymphedema vs Chronic Lymphedema: When using this lymphedema model, we found that to study the effect of our alginate gels in acute lymphedema (14 and 28 days) was possible ( Figure 7) . However, when we tried to maintain the model for a longer period of time, about 3 months it was very difficult to attain. The animals had to be subjected to a second or even third "injury" procedure, and even in those cases we were not able to see the adipose atrophic changes that one sees in chronic lymphedema patients.
Last Phase of

Figure 7
Physiological Assessment of Transplanted Animals. At 14 and 28 days after transplantation, Lymphocintography studies were conducted to assess lymphatic regeneration. Immediately before sacrifice, mice were injected with an overdose of pentobarbital.
In the control animals, the tail lymphatic circulation was interrupted, while the test, alginate gel (VEGF-C & Ang-2) were able to induce linphoangiogenesis and restore normal lymphatic flow through the mouse tail. (Figure 8 ). Our Specific aims for this award were completed.
We were able to incorporate into our previous porous, biodegradable alginate gel with VEGF-C a second growth factor, Ang-2 to serve as a receptor agonist, thus enhance the VEGF-C mitogenic effect in promoting Lymphatic Endothelial Cell proliferation and migration in vitro.
We induced (surgically) lymphedema of the tail of mice to inject the VEGF-C and Ang-2 alginate gels to evaluate lymphoangiogenesis in vivo.
Reportable Outcomes:
Rat Thoracic Duct Cell line maintained. 
Conclusions:
A biodegradable Alginate gel, may be an effective delivery system for sustained slow release of VEGF-C and Ang-2 to promote lymphangiogenesis in those instances where the integrity of the VEGF-3 and Tie-2 receptor of the LEC are intact.
Our lymphedema tail model proved to be a good model to induce acute lymphedema and test our alginate gels with growth factors VEGF-C and Ang-2. However, this is not a good model to assess chronic lymphedema.
To sustain the lymphedematous tail for prolonged periods of time (3 or more months) proved to be very difficult to obtain. Often times having to re-injure the lymphatics at the wound site. There were no atrophic adipose tissue changes as those seen clinically in patients with secondary lymphedema. Thus, the hopes to try out these gels in chronic lymphedema and subsequent restoration of lymphatic flow by inducing lymphoangiogenesis could not be assessed. Perhaps a different animal model for lymphedema, where there is more adipose tissue on the underlying lymphatic bed, could yield the answers that we are seeking.
We will continue to look for a suitable model to try out this new therapy in the hopes that perhaps some day in the near future we could offer hope in treating this disease for which there is no cure. 
